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Monocytes and macrophages play a central role in viral infections, as a target for viruses and in activation of both innate
and adaptive immune responses. Epstein–Barr virus (EBV) has evolved elaborate strategies to dampen the immune system
and to persist within the host. There is evidence that the product of the BCRF-1 open reading frame of EBV, viral interleukin-10
(vIL-10), inhibits the capacity of monocytes/macrophages to induce T cell activation, but the full mechanism of this effect is
unknown. To determine whether this effect might involve modulation of the expression of accessory molecules known to be
important in T cell activation, we analyzed by flow cytometry the influence of vIL-10 on the basal as well as on IFN--induced
up-regulation of HLA molecules, ICAM-1, and two members of the B7 family B7.1 (CD80) and B7.2 (CD86) at the surface of
human monocytes. Viral IL-10 in a concentration-dependent manner inhibited both basal- and IFN--induced HLA-class II,
ICAM-1 (basal levels of ICAM-2 and ICAM-3 is unaffected), CD80, and CD86 up-regulation when added simultaneously with
IFN-. In contrast, complete inhibition of HLA-class I expression on monocytes/macrophages occurred only when vIL-10 was
present 2 h prior to the addition of IFN-, implying that vIL-10 affects an early step in the IFN- signaling pathway. As both
monocytes and macrophages can be infected by EBV, we propose that vIL-10-mediated impairment of monocyte/macro-
phage antigen-presenting function could help the virus-infected cells to avoid detection by the host’s T cells on one hand andKey Words: vIL-10; B7; HLA; intercellular adhesion mole
INTRODUCTION
Epstein–Barr virus (EBV) is a ubiquitous humangamma-
herpesvirus, which is widespread in approximately 90%
of the world population. EBV is the causative agent of
infectious mononucleosis (IM) and is associated with a
range of malignant human diseases including Burkitt’s
lymphoma (BL), Hodgkin’s disease (HD), undifferentiated
nasopharyngeal carcinoma (NPC), and immunoblastic
lymphomas in immunosuppressed individuals, espe-
cially transplant patients and AIDS patients (Khanna et
al., 1995; Kawa, 2000).
Although the primary targets of EBV were believed to
be mainly B cells and epithelial cells of the oropharynx,
more recently, it has been observed that EBV can infect
and replicate in human monocytes (Savard et al., 2000)
and macrophages (Shimakage et al., 1999). Monocytes
and macrophages are rapidly mobilized in tissues in the
early phases of viral infection and exert a significant
influence on almost all aspects of immunological and
inflammatory responses (Guidotti and Chisari, 2001). In
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addition to their key role in innate immunity, monocyte/
macrophages play an essential role in the induction and
regulation of specific antiviral T cell responses through
binding of antigenic–major histocompatibility complexes
(MHC) to specific T cell receptor (TCR) complex and
release of immunomodulatory cytokines (Guidotti and
Chisari, 2001; Sigal et al., 1999). A role for macrophages
in activation of EBV-specific cytotoxic T lymphocytes
(CTL) was demonstrated by Bejarano et al. (1990). In their
study macrophages were shown to be as efficient as B
cells in processing the virus and stimulating specific T
cell responses manifested as the capacity of T cells to
inhibit EBV-induced B cell transformation (Bejarano et al.,
1990).
A critical feature of macrophages, which enables them
to activate T cells, is their ability to deliver costimulatory
(or secondary) signals to T cells through the ligation of
various molecules with their counterreceptors present
on T cells. Among the different accessory molecules
expressed on macrophages, the members of the B7
family CD80 (B7.1) and CD86 (B7.2), and intracellular
adhesion molecule-1 (ICAM-1), were found to play major
roles in T cell activation by interacting with their coun-
terreceptors CD28/CTLA-4 and leukocyte function-asso-contribute to its immunosuppressive properties on the oth
Immunochemistry, 10355 Science Center Drive, San Diego, CA 92121.
Fax: (858) 558-3525. E-mail: ssalek@liai.org.
Virology 304, 342–351 (2002)
doi:10.1006/viro.2002.17162002 Elsevier Science (USA)
ciated antigen-1 (LFA-1), respectively (Croft, 1994; Croft
and Dubey, 1997; Watts and DeBenedette, 1999; Mueller,er. ©
cule-1;
2000). Interaction between TCR complex and antigen–
MHC complex in the absence of costimulation not only
results in the failure to induce an immune response, but
often also results in functional inactivation of mature T
cells, leading to a state of T cell unresponsiveness (an-
ergy) or death. Therefore, T cell costimulatory signals
play a critical role in determining the fate of a T cell that
initiates an immune response, impairment of which
could allow viral agents to evade T cell responses.
Herpes viruses and in particular EBV have evolved
elaborate strategies to avoid detection by the host im-
mune system and to persist chronically within the host
(Cohen, 1999; Redpath et al., 2001). Our laboratory has
been interested in the role of the EBV-encoded protein
BCRF1 in this process. BCRF1 is 84% identical in amino
acid sequence with the human interleukin-10 (hIL-10)
gene and shares some of its functional properties; hence
it was named viral IL-10 (vIL-10) (Moore et al., 1990; Vieira
et al., 1991). The exact role of vIL-10 in the EBV life cycle
is not clear; however, it has been proposed that vIL-10
may facilitate the establishment of latent infection by
inhibiting or partially reducing the host’s immunity, espe-
cially T cell responses (Swaminathan et al., 1993; Be-
jarano and Masucci, 1998; Muller et al., 1998; Moore et
al., 2001). However, the full mechanisms for the inhibitory
effect of vIL-10 are not defined.
Viral IL-10 has been previously shown to inhibit the
activation of human antigen-specific CD4 T cells and T
cell clones when monocytes but not when EBV-immor-
talized B cells (LCLs) were used as antigen-presenting
cells (de Waal Malefyt et al., 1991). Because vIL-10 was
shown to reduce Human Leukocyte Antigen (HLA)-class
II expression on monocytes and not on EBV-LCLs, it was
suggested that vIL-10 may inhibit antigen-specific CD4
T cell responses by reducing the antigen-presenting ca-
pacity of macrophages through down-regulation of MHC-
class II molecules (de Waal Malefyt et al., 1991). We
hypothesized that the capacity of vIL-10 to diminish CD4
and possibly CD8 T cell responses may also be due to its
effects on HLA-class I as well as adhesion/costimulatory
molecules ICAM-1, CD80, and CD86, all of which have
been implicated as important determinants for profes-
sional antigen-presenting cells.
ICAM-1 (Springer, 1990) and CD86 (Azuma et al., 1993)
are constitutively expressed at low levels on resting
human monocytes, while CD80 expression is very low or
undetectable (Freedman et al., 1991). In response to
cytokines such as IFN-, monocytes progress into a
state of activation that is accompanied by up-regulation
of HLA, ICAM-1, and B7 cell-surface expression and
acquisition of potent antigen-presenting capacity (Dustin
et al., 1989; Freedman et al., 1991; Willem et al., 1994;
Olikowsky et al., 1997). Relevant to this study, infection
with EBV in vitro (Gosselin et al., 1989) and in vivo
infection in the form of IM (Linde et al., 1992) results in
elevated IFN- levels in the supernatants of EBV-infected
peripheral blood mononuclear cells (PBMCs) and serum
of infected individuals, respectively. Therefore, during
EBV infection, newly recruited monocytes and tissue
macrophages that have been activated under the influ-
ence of IFN- could play a pivotal role in the activation of
EBV-specific T cell responses.
In this study we attempted to identify potential mech-
anisms by which vIL-10 inhibits the T cell stimulatory
capacity of monocytes/macrophages by analyzing the
influence of recombinant vIL-10 on the constitutive and
IFN--induced cell-surface expression of HLA-class I,
ICAM-1, and B7 on human monocytes.
RESULTS
Effect of vIL-10 on HLA-class I and II cell-surface
expression on monocytes/macrophages
Antigen-presenting capacity of APCs has been shown
to depend, among other factors, on the density of HLA-
class I and HLA-class II molecules accommodating the
relevant antigenic peptides. HLA-class I molecules bind
to short peptides that are generated through proteolysis
of endogenously synthesized cellular proteins in the cy-
tosol and present them to CD8 T cells. HLA-class II
molecules are responsible for antigen-specific activation
of CD4 helper T cells. Figs. 1A to 1C show that mono-
cyte/macrophage population within PBMCs was en-
riched to 96.84% by the chosen flow cytometry gating as
determined by the expression of the monocyte/macro-
phage-specific marker, CD14, within the gated region R2.
We first confirmed previous data indicating that vIL-10
decreased the constitutive (Fig. 1D) and IFN--induced
(Fig. 1E) HLA-class II cell-surface expression on mono-
cytes. The effect of vIL-10 on the constitutive and IFN--
induced expression of HLA-class I molecules on mono-
cyte/macrophages was examined next. Figure 1 shows
that in contrast to HLA-class II, vIL-10 did not influence
the constitutive (Figs. 1G and 1H) or IFN--induced (Figs.
1I and 1J) HLA-class I cell-surface expression on mono-
cytes. Additional experiments examined the effects of
pretreating PBMCs with vIL-10 on the IFN--induced
HLA-class II (Fig. 1F) and HLA-class I (Figs. 1K and 1L)
cell-surface expression on monocyte/macrophages. As a
positive control for our vIL-10 preparation, the effect of
recombinant human IL-10 (hIL-10) was also examined
and compared with vIL-10. Stimulation of PBMCs with
IFN- alone for 24 h increased the levels of HLA-class II
(Fig. 1F) and HLA-class I molecules (Figs. 1K and 1L) on
monocyte/macrophages by 2.96- and 1.36-fold, respec-
tively, compared with cells cultured in medium alone.
Addition of IL-10 at the beginning of culture period for 2 h
only prior to IFN- exposure completely inhibited the
IFN--induced expression of HLA-class II and HLA-class
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I molecules on monocyte/macrophages. Interestingly,
despite vIL-10’s 1000-fold lower affinity for the hIL-10
receptor (Liu et al., 1997), vIL-10 showed comparable
inhibitory effects to hIL-10 on IFN--induced HLA cell-
surface expression (Figs. 1F and 1L). The ability of vIL-10
to inhibit HLA-class I expression on monocytes implies
for the first time that vIL-10 could reduce monocyte/
macrophage-dependent activation of CD8 T cells.
FIG. 1. Viral IL-10 inhibits the IFN--induced HLA-class I and class II cell-surface expression on monocytes/macrophages. (A) Typical dot plot of human
PBMCs. The intensity of forward scatter (FSC; x-axis) is plotted against the intensity right angle scatter (SSC; y-axis) for each cell. (B) The monocyte/
macrophage population within PBMCs was gated out on the basis of their forward- and side-scatter characteristics (R2). (C) Histograms show the log
fluorescence intensity of CD14 (monocyte/macrophage-specific cell-surface marker) staining (x-axis) for cells in gated region R2 plotted against relative cell
number (y-axis) and superimposed on an isotype-matched control mAb (filled histograms) as indicated. The percentage of CD14 cells within the gated
region R2 is shown. PBMCs were cultured in growth medium alone or in the presence vIL-10 (0.1 to 100 ng/ml) (D, G, and H) or IFN- (10 ng/ml) plus the
indicated concentrations of vIL-10 (E, I, and J). Alternatively, hIL-10 or vIL-10 (50 ng/ml) was added at the beginning of culture for 2 h and then washed out
prior to IFN- (10 ng/ml) exposure for the last 22 h of culture (F, K, and L). Histograms show the log fluorescence intensity of HLA-class I staining (x-axis;
G, I, and K) plotted against relative cell number (y-axis) as indicated. For clarity, only the histogram for the highest concentration of vIL-10 used is shown.
The gated region is indicated by M1. HLA-class II (D, E, and F) and HLA-class I (H, J, and I) cell-surface expression on monocytes/macrophages were
determined by FACS and are presented as geometric mean fluorescence intensity (MFI)  3 SD in M1. Data are representative of three separate
experiments. Data marked * are statistically significant (P  0.001) comparing untreated or IFN- treated in the presence or absence of IL-10 by ANOVA.
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Effect of vIL-10 on ICAM-1 to -3 cell-surface
expression on monocytes/macrophages
We investigated whether vIL-10 could also influence
the cell-surface expression of other molecules known to
play important roles in T cell activation. The adhesion
molecules ICAM-1, ICAM-2, and ICAM-3 have been
shown to bind to their counterreceptors such as LFA-1
on T cells and facilitate the formation of stable APC:T cell
conjugates (Springer, 1990; Sedwick et al., 1999; Wulfing
et al., 1998a, b). This step is of critical importance in
activation of naive T cells, in particular at low ligand
concentrations (Bachmann et al., 1997). Increased adhe-
sion has been reported to lower the effective dose of
antigen required to reach a minimal threshold number of
activated TCR complexes by 100- to 10,000-fold (Bach-
mann et al., 1997; Abraham et al., 1999). In addition,
binding of ICAMs to LFA-1 has been shown to result in
increased levels of intracellular Ca2 flux, cytokine pro-
duction, and costimulatory signals (Croft, 1997; Watts et
al., 1999; Bleijs et al., 1999). To determine whether vIL-10
could influence ICAM cell-surface expression, PBMCs
were cultured for 24 h in the presence or absence of
increasing concentrations of vIL-10, and ICAM expres-
sion on monocytes/macrophages was analyzed by direct
immunofluorescence and FACS. The results in Figs. 2A
and 2B show that vIL-10 down-regulates the constitutive
expression of ICAM-1 in a concentration-dependent
manner. The maximum percentage inhibition of basal
ICAM-1 expression ranged between 29.65 and 38.82%
with vIL-10 concentrations of 50 and 100 ng/ml, respec-
tively. Since exogenous vIL-10 reproducibly inhibited the
basal expression of ICAM-1, the question of whether
vIL-10 affects the IFN--induced ICAM-1 expression was
also addressed. Results in Figs. 2C and 2D show that
IFN- stimulation increased the cell-surface expression
of ICAM-1 expression on monocytes/macrophages by
2.59-fold compared with cells cultured in medium alone.
Simultaneous addition of vIL-10 with IFN- reduced the
IFN--induced up-regulation of ICAM-1 at the surface of
monocytes/macrophages in a concentration-dependent
manner. Maximal inhibition was observed with vIL-10
concentrations of between 50 and 100 ng/ml correspond-
ing to a reduction of between 56.17 and 64.68%, respec-
tively. Consistent with the data obtained for HLA-class I
expression, results in Figs. 2E and 2F show that pretreat-
ment of PBMCs with vIL-10 or hIL-10 for 2 h only prior to
IFN- exposure enhanced the inhibitory effect of IL-10 on
IFN--induced ICAM-1 expression with complete inhibi-
tion occurring at 50 ng/ml compared with 56.17% when
they were present at the same time (compare Figs. 2D
and 2F). Moreover, concurrent addition of anti-vIL-10
neutralizing antibody with vIL-10 prior to IFN- stimula-
tion completely abrogated the inhibitory effect of vIL-10
on IFN--induced ICAM-1 expression (Fig. 2F); hence,
FIG. 2. Viral IL-10 inhibits the constitutive and IFN--induced ICAM-1 cell-surface expression on monocytes/macrophages. PBMCs were cultured
in growth medium alone or in the presence viral IL-10 (0.1 to 100 ng/ml) (A and B) or IFN- (10 ng/ml) plus the indicated concentrations of vIL-10 (C
and D). Alternatively, hIL-10, vIL-10 (50 ng/ml), or vIL-10 plus a neutralizing mAb to vIL-10 (vIL-10; 10 g/ml) was added at the beginning of culture
for 2 h and then washed out prior to IFN- (10 ng/ml) exposure for the last 22 h of culture (E and F). After one day, cells were harvested and stained
with FITC-conjugated mouse anti-human ICAM-1 antibody. ICAM-1 cell-surface expression on monocytes/macrophages were determined by FACS
and are presented as histograms (A, C, and E) and geometric mean fluorescence intensity (MFI)  3 SD in M1 (B, D, and F) as described in Fig. 1.
Data are representative of three separate experiments. Data marked * are statistically significant (P  0.001) comparing untreated or IFN- treated
in the presence or absence of IL-10 by ANOVA.
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demonstrating that the observed effect is specific to
vIL-10 and not the result of some hypothetical and cryptic
contaminant in the vIL-10 preparation. The results in Fig.
3 show that vIL-10 or hIL-10 did not affect the constitutive
or IFN--induced expression of ICAM-2 (Figs. 3A, 3C,
and 3D) or ICAM-3 (Fig. 3B and data not shown). Simi-
larly, pretreatment of monocytes/macrophages with
vIL-10 prior to IFN- exposure did not affect the stimula-
tory effect of IFN- on ICAM-2 and ICAM-3. Taken to-
gether, these results demonstrate that the inhibitory ef-
fect of vIL-10 on ICAM molecules is specific for ICAM-1.
Effect of vIL-10 on B7 cell-surface expression on
monocytes/macrophages
While the interaction between LFA-1 and ICAM-1
clearly plays an important role in T cell activation, more
recent studies have demonstrated that in the absence of
additional molecules, ICAM-1 induces insufficient IL-2 to
allow clonal expansion and T cells die by apoptosis 4 to
5 days after stimulation (Dubey et al., 1995; Zuckerman et
al., 1998). In this regard, several studies have shown that
following a TCR-mediated signal, ligation of CD28 on T
cells with B7.1 (CD80) and B7.2 (CD86) on APC allows T
cells to sustain proliferation by maximizing IL-2 produc-
tion (Lenschow et al., 1996; Appleman et al., 2000). In
addition, CD28 ligation provides an essential cell sur-
vival signal mediated in part, by inducing Bcl-x, which
prevents apoptosis or the induction of anergy that may
occur in response to TCR/HLA or TCR/HLA plus LFA-1/
ICAM-1 alone (Boise et al., 1995). As the levels of B7
expression have been shown to be related to macro-
phage costimulatory activity (Ding et al., 1993), we next
examined the effects of vIL-10 on the constitutive and
IFN--induced CD80 and CD86 expression on mono-
cytes/macrophages.
In agreement with previously published reports
(Azuma et al., 1993; Freedman et al., 1991), results in Fig.
4 show that the constitutive levels of CD80 (mean fluo-
rescence intensity, MFI, of 4.18 (0.11); Fig. 4A) on mono-
cytes/macrophages was considerably lower than that of
CD86 (MFI of 46.80 (5); Fig. 4B) at day 1. Consistent
with these observations, addition of vIL-10 had little or no
effect on CD80 (Fig. 4A) expression, whereas it down-
regulated CD86 expression (Fig. 4B). Incubation of PB-
MCs with IFN- for 24 h increased CD80 (Figs. 4C and
4D) and CD86 (Figs. 4G and 4H) expression on mono-
cytes/macrophages by 16.95- and 2.75-fold, respectively,
compared with control cells cultured in medium alone.
Concurrent addition of vIL-10 and IFN- to PBMCs at the
beginning of the culture period inhibited the IFN--in-
duced CD80 (Figs. 4C and 4D) and CD86 (Figs. 4G and
4H) expression on monocytes/macrophages in a con-
centration-dependent manner. Optimal inhibitory con-
centrations of vIL-10 on CD80 expression were between
10 and 50 ng/ml, which in repeated experiments of this
type resulted in between 5.13 and 40.74% inhibition of
IFN- response. The inhibitory effect of vIL-10 on CD86
expression was more pronounced than that on CD80
with almost complete inhibition (86.93%) occurring with
vIL-10 concentrations of 10 ng/ml. Results depicted in
Figs. 4E and 4F show that pretreatment of PBMCs with
vIL-10 for 2 h before the addition of IFN- enhanced the
inhibitory effect of vIL-10 on CD80 expression by 1.69-fold
(compare Figs. 4D and 4F), whereas it did not further
enhance its effect on CD86 (compare Figs. 4H and 4J).
DISCUSSION
There is now strong evidence that EBV-specific T lym-
phocytes are responsible for limiting the expansion of
latently infected cells as well as reducing virus load by
targeting productively infected cells expressing lytic an-
tigens (Rickinson and Moss, 1997). In view of the critical
role played by macrophages in activation of T cells, it
seems logical that defects in their antigen-presenting
cell (APC) function after infection with EBV could provide
a selective advantage for ensuring propagation and per-
FIG. 3. Viral IL-10 does not affect the cell-surface expression of
ICAM-2 and ICAM-3 on monocytes/macrophages. Histograms show
the log fluorescence intensity of ICAM-2 (A and C) or ICAM-3 (B)
staining ( x-axis) plotted against the relative cell number ( y-axis) after
culture of PBMCs in growth medium alone or vIL-10 (100 ng/ml) or
IFN- (10 ng/ml) plus the indicated concentrations of vIL-10 (D) and
superimposed on an isotype-matched control mAb (filled histogram).
ICAM cell-surface expression on monocytes/macrophages were deter-
mined by FACS and are presented as geometric mean fluorescence
intensity  3 SD (MFI) in gated region M1 (B, D, and F) as described in
Fig. 1. Data are representative of two separate experiments. Data
marked * are statistically significant (P  0.001) comparing untreated
or IFN- treated in the presence or absence of IL-10 by ANOVA.
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sistence within the host. Accordingly, and consistent with
previously published data on purified human monocytes,
we have shown that EBV, through vIL-10, can down-
regulate both constitutive and IFN--induced HLA-class
II cell-surface expression on monocytes/macrophages
within PBMCs. The present article, however, suggests an
additional advantage for the virus in capturing this cyto-
kine homologue, namely the complete suppression of
IFN--induced HLA-class I on monocytes/macrophages.
Interestingly, this effect was seen only when vIL-10 was
present 2 h prior to IFN- exposure but not at the same
time, implying that vIL-10 affects an early step in the
IFN- signaling pathway. In support of this hypothesis,
hIL-10 has been shown to inhibit IFN--induced cytokine
production in human monocytes by rapidly inducing
(within 30 min) the expression of the suppressor of cy-
tokine signaling-3 (SOCS-3) gene, which leads to the
suppression of IFN--induced tyrosine phosphorylation
and nuclear translocation of STAT1 (Ito et al., 1999).
During primary infection with EBV in the form of infec-
tious mononucleosis, abnormally high serum levels of
vIL-10 (100–300 pg/ml) can be detected (Taga et al.,
1995). Viral IL-10 is produced during the late phase of the
lytic cycle (Hudson et al., 1985; Stewart et al., 1994), but
it has also been detected by reverse transcriptase-poly-
merase chain reaction immediately (within 6 h) after viral
infection (Miyazaki et al., 1993). This early expression of
the viral product is followed by the virally induced IFN-
secretion, starting at 12 h postinfection and peaking at 7
days postinfection (Gosselin et al., 1989). Human IL-10
(4–10 ng/ml) first appears 3–4 days postinfection with
EBV and peaks at 14 days postinfection (Burdin et al.,
1993). These kinetics are consistent with our data, show-
ing that vIL-10 exhibits maximal activity when present
prior to IFN- and further highlights the requirement for
EBV to encode its own homologue of cellular IL-10. The
levels of vIL-10 (10–50 ng/ml) used in our assays to
achieve complete inhibition of HLA and costimulatory
molecules were approximately 10-fold higher than this,
but in the microenvironment surrounding an infected cell
it is possible that the local concentrations of vIL-10 could
exceed this value through its ability to interact with cell-
surface glycosaminoglycans (GAGs) such as heparin
and heparan sulfate (Salek-Ardakani et al., 2000, 2002).
Furthermore, the effect of vIL-10 on IFN- activity was
investigated using optimal concentrations of IFN- (10
FIG. 4. Viral IL-10 inhibits the IFN--induced CD80 and CD86 cell-
surface expression on monocytes/macrophages. Histograms show the
log fluorescence intensity of CD80 (A, C, and E) and CD86 (B, G, and I)
staining ( x-axis) after culture of PBMCs in growth medium alone or
vIL-10 (100 ng/ml) plotted against the relative cell number ( y-axis) and
superimposed on an isotype-matched control mAb (filled histogram). In
addition, PBMCs were cultured in growth medium alone or in the
presence IFN- (10 ng/ml) plus the indicated concentrations of vIL-10
(C, D, G, and H). Alternatively, IL-10 (50 ng/ml) was added at the
beginning of culture for 2 h and then washed out prior to IFN- (10
ng/ml) exposure for the last 22 h of culture (E, F, I, and J). After 1 day,
cells were harvested and stained with either PE- and FITC-conjugated
mouse anti-human CD80 and CD86 antibody, respectively. CD80 and
CD86 cell-surface expression on monocytes/macrophages were deter-
mined by FACS and are presented as geometric mean fluorescence
intensity (MFI)  3 SD as described in Fig. 1. Data are representative
of three separate experiments. Data marked * are statistically signifi-
cant (P  0.001) comparing untreated or IFN- treated in the presence
or absence of IL-10 by ANOVA.
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ng/ml), which may have some reflection on the dose of
vIL-10 required to inhibit its function.
Expression of vIL-10 during the initial stages of EBV
infection and the subsequent down-regulation of HLA-
class I and II molecules delineate potential mechanisms
by which EBV immediately begins to interfere with the
host adaptive immune system and would be likely to
impair the capacity of infected macrophages to present
antigenic viral peptides to CD8 and CD4 T cells, re-
spectively. This assumption is substantiated by previous
reports showing that vIL-10 suppresses antigen-specific
T cell responses by down-regulating HLA-class II mole-
cules on monocytes (de Waal Malefyt et al., 1991), and by
down-regulating HLA-class I molecules on B cells and
melonoma cells (Zeidler et al., 1997; Matsuda et al.,
1994). Interestingly, another herpesvirus, cytomegalovi-
rus (CMV), down-regulates HLA-class II molecules on
infected macrophages through the rapid (within 24 h)
induction of hIL-10 production in infected cells (Redpath
et al., 1999). Whether EBV infection of monocytes/mac-
rophages also induces hIL-10 is an area that requires
further investigation.
While inhibition of antigen presentation via HLA-class
I and II pathways in EBV-infected and tumor cells may be
the most intensively studied, it is by no means the only,
or the most frequently used, viral escape mechanism (for
review, see Sharpe, 1996). The present article suggests a
fundamentally different strategy utilized by EBV to inter-
fere with the host T cell response, namely the vIL-10-
induced down-regulation of constitutive and IFN--in-
duced adhesion/costimulatory molecules, ICAM-1, CD80,
and CD86 on monocytes/macrophages. ICAM-1 is
thought to function to promote APC:T cell conjugates
(Wulfing et al., 1998a, b), lower the concentration of
antigen required for T cell stimulation, and promote sus-
tained signaling from the TCR (Bachmann et al., 1997;
Abraham et al., 1999). The interaction of CD80 and CD86
with their counterreceptor, CD28, on T cells on the other
hand, is crucial for sustained T cell proliferation, up-
regulation of IL-2 receptors , , and , induction of many
cytokine genes including IL-2, and blocking of apoptosis
(Boise et al., 1995). On resting monocytes ICAM-1
(Springer, 1990) and CD86 (Azuma et al., 1993) are con-
stitutively expressed at low levels, while CD80 expres-
sion is very low or undetectable (Freedman et al., 1991).
Consistent with these observations, monocytes have
been shown to be poor at stimulating T cell proliferation
and effector function. Therefore, it is conceivable that the
vIL-10-induced decrease (albeit modest; 20–40%) in
basal levels of ICAM-1, CD80, and CD86 on resting hu-
man monocytes would further diminish their capacity to
function as professional APCs. In support of this notion,
addition of vIL-10 (100 ng/ml) to BM-derived murine den-
dritic cells (DC) propagated in GM-CSF plus IL-4 or
vIL-10 gene transduction of DC has been shown to re-
duce (by between 20 and 50%) the percentage of ICAM-1,
CD80, and CD86 positive dendritic cells and markedly
inhibit their ability to induce T cell proliferation and CTL
generation and promote the induction of T cell hypore-
sponsiveness (Takayama et al., 1998, 1999, 2001).
In contrast to monocytes, activated macrophages have
been shown to be very effective in presenting antigenic
peptides to T cells and stimulating the generation of CTL
directed against a number of viruses including EBV (Tou-
jas et al., 1997; Bejarano et al., 1990). The differentiation
of monocytes to macrophages is strictly regulated by
extracellular stimuli such as cytokines. IFN- primes
monocytes to differentiate into macrophages with potent
T cell stimulating capacity, which is partly dependent on
its ability to up-regulate the cell-surface expression of
HLA, ICAMs, and B7 molecules on these cells (Dustin et
al., 1989; Freedman et al., 1991; Olikowsky et al., 1997;
Willems et al., 1994). In this study we have shown for the
first time that concurrent addition of vIL-10 with IFN-
inhibits (by between 40 and 90%) the IFN--induced
ICAM-1, CD80, and CD86 expression on monocytes. In-
terestingly and consistent with the HLA-class I data,
exposure of monocyte cultures to vIL-10 for only 2 h prior
to IFN- stimulation completely inhibited the stimulatory
effect of IFN- on ICAM-1, CD80, and CD86. Taken to-
gether, our results imply that the vIL-10-mediated
ICAM-1, CD80, and CD86 down-regulation on mono-
cytes/macrophages could contribute to impaired T cell
activation and TCR signaling and render antiviral T cells
tolerant by inducing an unresponsive state (anergy).
Consistent with this notion, hIL-10 has been shown to
induce a long lasting anergic state in human T cells
when added concomitantly with antigen in the presence
of monocytes (Groux et al., 1996, 1997, 1998). This effect
is mediated in part by the down-regulation of ICAM-1,
CD80, and CD86 on monocytes by hIL-10 (Willems et al.,
1994; Ding et al., 1993).
There is a precedent for viral infection of monocytes/
macrophages and other cells resulting in alterations of
adhesion costimulatory molecules. HIV and human rhi-
noviruses down-regulate CD86 and ICAM-1 cell-surface
expression on infected monocytes which is mediated in
part through the induction of cellular IL-10 (Sharpe, 1996;
Stockl et al., 1999). More recently, the product of the
Kaposi’s sarcoma-associated herpesvirus (KSHV) gene,
K5, has been shown selectively to down-regulate ICAM-1
and CD86 (but not CD80) expression on B cells, conse-
quently impairing their ability to activate T cells (Coscoy
and Ganem, 2001). However, our study is the first dem-
onstration of a virally encoded cytokine that down-regu-
lates the expression of ICAM-1, CD80, and CD86 on
human monocytes/macrophages. More importantly, we
show that despite vIL-10’s 1000-fold lower affinity for the
hIL-10 receptor (Liu et al., 1997) its effects on ICAM-1,
CD80, and CD86 are comparable to that of hIL-10. Thus,
we propose that down-regulation of proteins associated
with costimulation by autocrine and/or paracrine secre-
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tion of vIL-10 is likely to be important in the ability of EBV
to impair T cell activation by infected macrophages dur-
ing the first critical days after primary infection, when the
number of infected cells are small and the levels of
soluble viral particles and antigens are low. These con-
ditions increase the requirement for costimulatory sig-
nals. It is also likely that vIL-10 plays an essential role
during subsequent reactivation of the virus by dampen-
ing memory T cell responses targeted against produc-
tively infected cells expressing lytic antigens. Further-
more, the fact that EBV can infect monocytes (Savard et
al., 2000) and macrophages (Shimakage et al., 1999)
suggests that the diminished T cell recognition of mono-
cytes/macrophages by vIL-10 may not only serve as a
means by which EBV affects the immune system, but
could also enable them to serve as a reservoir and a
vehicle for the dissemination of the virus throughout the
host.
Relevant to the immunosuppressive properties of
vIL-10 is also its capacity to inhibit the production of
IFN-, which is important in the early control of EBV
infection and transformation (Swaminathan et al., 1993;
Thorley Lawson, 1981; Lotz et al., 1985; Gosselin et al.,
1989). The present findings concerning the inhibition of
IFN--induced cell-surface expression of activation
markers on monocytes/macrophages by addition of
vIL-10 does further support the conclusion that an impor-
tant role for vIL-10 in vivo is to suppress any IFN--
mediated immune responses to EBV infection. Viral IL-10
has numerous other inhibitory effects on monocytes/
macrophages function, some of which include suppres-
sion of proinflammatory cytokines (most notably IL-12,
IL-18, and TNF-) and chemokines (Moore et al., 2001).
Collectively, these data suggest that concurrent inhibi-
tion of proinflammatory mediators and antigen-present-
ing capacity of monocytes/macrophages through induc-
tion of vIL-10 is likely to represent an evolutionary ad-
vantage for ensuring propagation and persistence of
EBV within the host.
MATERIALS AND METHODS
Cytokines and reagents
Recombinant vIL-10 was expressed using the bacterial
expression vector pMAL-c2 and purified by a combina-
tion of amylose resin and heparin agarose chromatog-
raphy as described previously (Salek-Ardakani et al.,
2002). Recombinant human IL-10 (hIL-10; used as a pos-
itive control) and IFN- expressed in Escherichia coli
were obtained from Pepro Tech (U.K.) and R&D Systems,
respectively. FITC-conjugated HLA-A, -B, -C (HLA-class I;
G46–2.6), RPE-conjugated CD80 (B7.1; BB1), and FITC-
conjugated CD86 (B7.2; 2331 (FUN)) mouse anti-human
monoclonal antibodies were from PharMingen. FITC-
conjugated CD14 (TUK4), HLA-DP, -DQ, -DR (HLA-class
II; CR3/43), and CD54 (ICAM-1; 6.5B5) mouse anti-human
monoclonal antibodies were from DAKO. FITC-conju-
gated CD50 (ICAM-3; Cal 3.10) and CD102 (ICAM-2; B-T1)
mouse anti-human monoclonal antibodies were from
R&D Systems and Serotec, respectively.
Cell preparation and culture
Peripheral blood mononuclear cells were isolated
from healthy donors as described previously (Salek-
Ardakani et al., 2000). PBMCs were cultured for 24 h at a
density of 1.5  106 cells/ml in HEPES (25 mM)-buffered
RPMI 1640 supplemented with 100 U/ml penicillin and
100 g/ml streptomycin, 2 mM L-glutamine, and 10% fetal
calf serum (FCS) (all from Gibco) in growth medium alone
or in the presence of IL-10 (0.1 to 100 ng/ml), IFN- (10
ng/ml), or IFN- plus increasing concentrations of IL-10.
In some experiments IL-10 (50 ng/ml) was added at the
beginning of culture for 2 h with or without anti-vIL-10-
neutralizing antibody (vIL-10; 10 g/ml) and then
washed out prior to IFN- (10 ng/ml) exposure for the last
22 h of culture. After the incubation period, cells were
pelleted by centrifugation at 200 g for 3 min, followed by
resuspension in 200 l phosphate-buffered saline (PBS).
The cell-surface levels of HLA molecules, ICAMs, and B7
on monocytes/macrophages were determined by direct
immunofluorescence and analyzed by flow cytometry.
Immunofluorescence staining of cells for FACS
analysis
Harvested PBMCs were washed twice with PBS, 2%
bovine serum albumin (BSA), and 0.02% sodium azide
(FACS buffer) by centrifugation and resuspended in 50 l
ice-cold FACS buffer containing FITC-conjugated detect-
ing monoclonal antibody followed by incubation in the
dark at 4°C for 30 min. Subsequently, cells were washed
three times with FACS buffer and resuspended in 200 l
of PBS containing 1% formaldehyde. After a further incu-
bation period of 1 h on ice, cells were washed and
resuspended in 200 l FACS buffer before analysis. Im-
munostained cells were analyzed on a FACScan flow
cytometer (Becton–Dickinson) using CELLQest software.
Binding of antibodies was evaluated on monocyte/mac-
rophage populations, which had been gated within
PBMCs by forward- and side-scatter patterns; the cells
excluded from analysis were smaller and comprised
5% of the cell population. Monocyte/macrophage en-
richment to 90% by the chosen flow cytometry gating
was routinely confirmed by the expression of the mono-
cyte-specific marker, CD14, of an identically gated con-
trol cell suspension (Figs. 1A to 1C). A minimum of 10,000
events gated for the forward- and side-scatter parame-
ters characteristic of monocyte/macrophages were ac-
quired. The results are expressed as MFI  3 SD.
Control of endotoxin levels. All cell-culture reagents
used were either certified as low in endotoxin when
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purchased or were ensured to be low in endotoxin by the
Kinetic-QCL (BioWhittaker) assay.
Statistical analyses. Data are mean 3 standard er-
rors of the mean (SEM) and are representative of at least
three experiments. Results were assessed for statistical
significance using a two-way analysis of variance
(ANOVA) test. *P  0.001 was taken as the threshold of
significance.
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